BF2.649 in Patients With OSA and Treated by CPAP But Still Complaining of EDS (HAROSA1)

This study has been completed.

Sponsor:

Information provided by (Responsible Party):

Bioprojet

ClinicalTrials.gov Identifier:

NCT01071876

First received: February 18, 2010

Last updated: January 20, 2015

Last verified: January 2015

History of Changes

Purpose

Multicenter randomized double blind study versus placebo during 12 weeks with at first, an escalating dose period followed by stable dose period at the selected dose.

This double-blind period can be followed by a 9 months open-label period if the patient wishes to continue with the study product.

Condition	Intervention	Phase
Obstructive Sleep Apnea Excessive Daytime Sleepiness	Drug: BF2.649 Drug: Placebo	Phase 3


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment
Official Title:	BF2.649 in Patients With Obstructive Sleep Apnea Syndrome (OSA) and Treated by Nasal Continuous Positive Airway Pressure (nCPAP), But Still Complaining of Excessive Daytime Sleepiness (EDS)

Resource links provided by NLM:

MedlinePlus related topics: Sleep Apnea

U.S. FDA Resources

Further study details as provided by Bioprojet:

Primary Outcome Measures:

ESS change (Epworth Sleepiness Scale) [ Time Frame: at week 12 /52 versus baseline ]


Enrollment:	244
Study Start Date:	August 2011
Study Completion Date:	March 2014
Primary Completion Date:	March 2014 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: BF2.649 BF2.649 capsules dosed at 5mg, 10 mg, 20mg	Drug: BF2.649 1 capsule in the morning before breakfast Other Name: Pitolisant
Placebo Comparator: Placebo Capsules of Placebo containing lactose with low, medium and high dosage	Drug: Placebo 1 capsule in the morning before breakfast

Detailed Description:

The first period (12 weeks double blind period) will aim at demonstrating the efficacy and safety of BF2.649 by verifying whether the results of BF2.649 are superior to those of placebo.

The aim of the second period (open label extension phase) will be to assess the long-term tolerance, as well as the maintenance of the BF2.649 efficacy.

Eligibility


Ages Eligible for Study:	18 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

patients with OSA treated by nCPAP but still complaining with EDS
ESS score > or = 12

Exclusion Criteria:

patient suffering from insomnia without OSA
co-existing narcolepsy
patient with sleep debt not due to OSA
acute or chronic severe disease

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01071876

Locations


France
CHU Grenoble
Grenoble, France

Sponsors and Collaborators

Bioprojet

Investigators


Study Director:	Evelyne De Paillette, MD	Bioprojet

More Information


Responsible Party:	Bioprojet
ClinicalTrials.gov Identifier:	NCT01071876 History of Changes
Other Study ID Numbers:	P09-08 / BF2.649 2009-017248-14 ( EudraCT Number )
Study First Received:	February 18, 2010
Last Updated:	January 20, 2015

Keywords provided by Bioprojet:


Sleep disorder obstructive sleep apnea excessive daytime sleepiness patients with OSA treated by CPAP presenting EDS

Additional relevant MeSH terms:


Apnea Sleep Apnea Syndromes Sleep Apnea, Obstructive Respiration Disorders Respiratory Tract Diseases Signs and Symptoms, Respiratory	Signs and Symptoms Sleep Disorders, Intrinsic Dyssomnias Sleep Wake Disorders Nervous System Diseases

ClinicalTrials.gov processed this record on June 23, 2017

To Top